Clinical Trial Update: A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of RSV preF-based vaccine formulations in adults aged 60+ was terminated with results posted in January 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV pre-Fusion-based vaccine (experimental)

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-01-02